Glaxosmithkline | GSK - Beneficio Bruto En Ventas

Precio De Mercado
58.97
Cambio Diario
-0.15 -0.25%
Mensual
-0.49%
Anual
70.24%
Q2 Expectativa
57.14




Beneficio Bruto En Ventas Cambio Fecha
AbbVie USD 10.47B 605M 2025-09
Amgen USD 6.48B 307M 2025-09
AstraZeneca USD 12.39B 5M 2025-12
Aurora Cannabis CAD 46.62M 14.33M 2025-12
Bausch Health Companies USD 1.93B 165M 2025-09
Bristol-Myers Squibb USD 8.79B 110M 2025-09
Canopy Growth CAD 21.47M 434K 2025-12
Corcept Therapeutics USD 199.58M 3.46M 2025-12
Drreddys Laboratories INR 46.81B 10.24B 2025-12
Eli Lilly USD 14.59B 1.48B 2025-09
GlaxoSmithKline GBP 6.18B 106M 2025-12
Glaxosmithkline GBP 8.75B 2.92B 2025-09
J&J USD 16.6B 118M 2025-12
Merck USD 13.42B 431M 2025-09
Novartis USD 10.25B 570M 2025-12
Pacira USD 142.25M 11.34M 2025-12
Perrigo USD 362.2M 14.9M 2025-12
Pfizer USD 3.54B 7.61B 2025-09
Phibro Animal Health USD 133.5M 12.6M 2025-12
Prestige Brands USD 157.37M 5.79M 2025-12
Roche Holding CHF 22.09B 10.04B 2025-12
Sanofi EUR 8.45B 1.31B 2025-12
Supernus Pharmaceuticals USD 164.04M 15.23M 2025-12
Takeda JPY 790.55B 262.97B 2025-12
Teva Pharmaceutical Industries USD 2.66B 351M 2025-12
Zoetis USD 1.64B 73M 2025-12